Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depression

NCT07836738 | Not Yet Recruiting DMC

• 1 other identifier: BoYi Medical Ethics No.1162026
• Study Type: interventional
• Target: 42
• Locations: 0 countries
• Sites: N/A

Brief Summary

\# Brief Summary This clinical research study looks at whether stellate ganglion block (SGB) can improve sleep quality for people with depression. Poor sleep often goes together with depression. Medicines used for these conditions may cause side-effects or dependency. Researchers want to learn if SGB, a minimally-invasive nerve treatment, can help sleep and mood without those medicine-related downsides. This study uses a self-controlled design. Every person who joins will receive the study treatment. No separate comparison group is enrolled. Researchers will collect sleep data from each participant before treatment and again after treatment, then compare these two sets of information. About 42 participants will take part in this study. Key requirements to join the study:

• Aged 18 to 65 years old
• Have depression-related symptoms and sleep trouble
• Able to understand and sign an informed consent form
• No medical conditions that make SGB unsafe
• Have not taken sleep-affecting medicines or received other sleep-focused treatments in the past one month
• Can follow study schedules and complete all study assessments People cannot join if they:
• Are younger than 18 years or older than 65 years
• Are pregnant or breastfeeding
• Have known allergies to study-used medicines
• Have unstable serious organ diseases, uncontrolled substance or alcohol dependence
• Cannot keep fixed daily routines or finish all study visits Study procedures for each participant:
• On study day zero (D0): Study staff will explain the study fully. Participants will sign informed consent. Staff will run physical checks and blood tests. Participants will fill out several simple questionnaires about mood and sleep. Sleep will be measured overnight with a multi-channel sleep recording device called polysomnography (PSG). Participants also keep a short sleep diary.
• From study day one (D1) to day five (D5): Participants get one SGB treatment each day, for a total of five treatments. During SGB, a doctor uses ultrasound guidance to inject small-dose local anesthetic near nerves in the neck. Participants keep completing their sleep diary every day. Study staff watch for any unwanted reactions during each treatment.
• On the night of D5 through early morning of D6: PSG sleep recording will be repeated after the final SGB treatment.
• On study day six (D6): Participants finish the final set of mood-and-sleep questionnaires. Study staff collect all safety information.

Conditions

Sleep and Circadian Problems

Outcome Measures

Primary Outcomes (6)

• Sleep Onset Latency, SOL

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

• Wake After Sleep Onset, WASO

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

• Total Sleep Time, TST

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

• Proportions of each non-rapid eye movement sleep stage

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

• Proportions of REM, NREM and Wake

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

• Sleep Efficiency, SE

  At baseline (Day 0) and from Night 5 to Morning 6 after intervention

Secondary Outcomes (4)

• Subjective sleep-onset latency

  30 minutes after awakening on the corresponding next morning

• Subjective Total Sleep Time

  30 minutes after awakening on the corresponding next morning

• Subjective Sleep Efficiency

  30 minutes after awakening on the corresponding next morning

• Sleep Satisfaction

  30 minutes after awakening on the corresponding next morning

Study Arms (1)

SGB group

EXPERIMENTAL

Stellate Ganglion Block

Procedure: Stellate Ganglion Block

Interventions

Stellate Ganglion Block PROCEDURE

Using an anterior-lateral approach, participants lie supine with head turned contralaterally to expose the neck. The interspace between the anterior sternocleidomastoid border, trachea and common carotid artery is identified. Skin is disinfected 3 times with iodophor (≥15 cm diameter), then covered with a sterile aperture drape. A 22-G needle is inserted vertically at the target site. After bony contact with the C6 transverse process, the needle is retracted 0.1-0.2 cm. With negative aspiration for blood and cerebrospinal fluid, inject 6 mL 0.25% ropivacaine (epinephrine 1:200 000) at 1 mL/min to limit bleeding and prolong block effect. Monitor blood pressure, heart rate, oxygen saturation, and adverse events (hoarseness, Horner syndrome, dyspnea) throughout injection.

SGB group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18-65 years of both genders. Alert and capable of normal communication. Voluntarily sign informed consent, complete the whole experimental procedure, and meet ethical and compliance requirements.
• Hamilton Depression Rating Scale (HAMD) score ≥ 8.
• Insomnia Severity Index (ISI) score ≥ 7 or Pittsburgh Sleep Quality Index (PSQI) score ≥ 7.
• No contraindications to stellate ganglion block (SGB); no cervical deformity, trauma, or infection; and no severe cervical spine disease, such as cervical fracture or cervical disc herniation with nerve compression.
• No use of sedative-hypnotics, anxiolytics, antidepressants, or other medications that may affect sleep within the past month, and no acupuncture, massage, nerve block, or other sleep-related interventions during the same period.
• Stable vital signs; normal liver and renal function, complete blood count, and coagulation function; and no severe organic diseases of the heart, brain, lungs, liver, or kidneys.
• Able to strictly follow the required sleep-wake schedule and cooperate with polysomnography (PSG) monitoring and completion of sleep diaries, with good study compliance.

You may not qualify if:

• : Age \<18 or \>65 years; pregnant or lactating women; subjects with psychiatric disorders (schizophrenia, mania, etc.) or cognitive impairment who cannot cooperate with the study, to prevent missing data and experimental bias.
• : Presence of contraindications to stellate ganglion block, such as coagulation disorders, local skin infection, severe cervical spine disease, hyperthyroidism, glaucoma, or increased intracranial pressure.
• : Allergy to ropivacaine, epinephrine, or other drugs used for the block, or a history of drug allergy.
• : Use of sedative-hypnotics, anxiolytics, antidepressants, hormonal medications, or other treatments that may affect sleep within the past month.
• : Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, hematologic disease, respiratory disease, or other serious organic diseases, or a recent history of surgery or trauma.
• : Alcohol dependence or drug dependence, or daily consumption of coffee, strong tea, or other stimulating beverages with inability to abstain during the study period.
• : Inability to maintain a fixed sleep-wake schedule during the study or inability to complete the full monitoring and intervention procedures because of work, daily life, or other reasons.
• : Voluntary withdrawal during the study, or inability to complete the study because of adverse reactions, poor compliance, or other reasons.

Sponsors & Collaborators

• Li Juan: lead

Related Publications (2)

• Liu Y, Liu L, Deng Z, Zhou Y, Xiao L, Tang Y. Application of stellate ganglion modulation in mental disorders and the future prospects of physical therapies. Fundam Res. 2025 Oct 23;6(1):548-559. doi: 10.1016/j.fmre.2025.09.024. eCollection 2026 Jan.

  PMID: 41647575 BACKGROUND

• Plante DT. The Evolving Nexus of Sleep and Depression. Am J Psychiatry. 2021 Oct 1;178(10):896-902. doi: 10.1176/appi.ajp.2021.21080821.

  PMID: 34592843 BACKGROUND

Central Study Contacts

tong fu, Master

CONTACT

+8613156561090; futong5533227@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: September 7, 2026
• First Posted: September 23, 2026
• Study Start: September 20, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: September 23, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will share